Pacific Biosciences of California, Inc. (PACB)
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-30
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-30
Research Workspace
Put PACB beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 94% growth a year, above the roughly 18% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 58% in its worst 12-month stretch.
View RiskPACB’s case rests on expanding SPRQ-Nx chemistry and Revio placements, though revenue growth is not reported. Recent financial performance is steady, and Q2 FY2026 non-GAAP EPS was inline. PACB trades at 6× sales versus a 3× peer median and 3× its own history. The market prices more growth than our forecast. Our model puts the next-quarter miss probability near 29%. That risk matters because the valuation already carries a large peer premium. Peer multiples imply a price about 94% below where it trades. Our standing thesis remains intact, though this read is provisional.
Trailing returns as of 2026-10-30. PACB is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering PACB (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare PACB with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PACB Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put PACB next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand commercial rollout of SPRQ-Nx chemistry and Revio system placements
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Partnership enhances commercial rollout of SPRQ-Nx chemistry.

Threatens: Achieve revenue guidance of $165M to $175M for 2026
Lowered revenue forecast impacts growth objectives.

Advances: Expand commercial rollout of SPRQ-Nx chemistry and Revio system placements
Earnings call confirms progress on SPRQ-Nx adoption.

New CEO may drive strategic growth initiatives.

New sequencing chemistry supports revenue growth.
Earnings miss could impact revenue guidance.
